The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 146 participants.
Also called NCT07897409
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 146 participants
- Sponsor
- Registry
-
NCT07897409
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07897409. Randomized; no masking; primary purpose prevention. Start 2026-12-01 (anticipated); primary completion 2027-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
- Acronym
- NICBREASTRCT
- Condition
- Doxorubicin Induced Cardiotoxicity
- Condition
- Doxorubicin Induced Cardiomyopathy
- Condition
- Doxorubicin
- Condition
- Doxorubicin Adverse Reaction
- Intervention (Drug)
- Nicorandil Oral Tablet
- Intervention (Drug)
- Adriamycin (Doxorubicin)
- Lead sponsor
- Universiti Sains Malaysia
Record details
- Record id
cardio:ct-nct07897409- Content hash
cf34a73b5aa2cc94eb9e1b098438e41f85db580e2d0942e0120e889761e499b6